Clinical Trial Update: To Compare the Efficacy and Safety of Tripterygium Wilfordii (TW) Versus Valsartan in the Membranous Nephropathy (MN) [Phase 4]

View source ↗

Summary

A Phase 4 trial completed comparing the efficacy and safety of Tripterygium wilfordii versus Valsartan in membranous nephropathy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Membranous Nephropathy

Drugs mentioned

• Tripterygium wilfordii (Tripterygium wilfordii)
• VALSARTAN (Valsartan)

Snippet

Sponsor: Nanjing University School of Medicine | Conditions: Membranous Nephropathy | Phase 4 | Status: COMPLETED